百奥泰：2025年净利润亏损3.36亿元

Core Viewpoint - The company reported a revenue of 934 million yuan for the fiscal year 2025, representing a year-on-year growth of 25.64%, while net profit showed a loss of 336 million yuan compared to a loss of 510 million yuan in the same period last year [1] Group 1 - The company actively expanded its market during the reporting period [1] - Sales of Adalimumab injection (Geleli) and Tocilizumab injection (Shilili) steadily increased compared to the same period last year [1] - The company launched Ustekinumab injection (STARJEMZA) in the United States, leading to growth in licensing income and sales revenue [1]